Latest Morning Briefing Stories
In other pharmaceutical news: Jonathan Sackler, co-owner of Purdue Pharma, dies at 65 of cancer; J&J lowers the price of a tuberculosis drug; the EPA approves Lysol to fight COVID-19; and more.
Whether or not the anti-malarial drug is effective has been a controversial question since President Donald Trump began hyping it in March. Now, Henry Ford Hospital researchers report a “significant reduction” in mortality rates with patients who were hospitalized between March 10 and May 2 and treated with it. But, adding to the debate around the drug’s power against the virus, the World Health Organization halts a trial using hydroxychloroquine and HIV treatment lopinavir-ritonavir in hospitalized COVID patients after interim results showed the drugs did not reduce mortality rates.
Editorial pages focus on these public health issues and others.
Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.
Read recent commentaries about drug-cost issues.
Editorial pages focus on these pandemic topics and others.
Because the drug can cause a potentially fatal condition called ketoacidosis in diabetic patients, advocates are calling on the FDA to issue a “black box” warning–the most severe that the agency can slap on a product. In other pharmaceutical news: fatty liver disease treatments, a biotechnology startup, and supplements.
News on the development of coronavirus vaccine and treatment is reported.
The decision from NIH is just the latest to signal that hydroxychloroquine, the drug President Donald Trump touted as a “game changer,” doesn’t work for COVID-19 patients. Meanwhile, scientists urge caution on a promising steroid treatment.
Scientists are worried a vaccine will be developed and work best in younger people–who are far less vulnerable to COVID than seniors are. Other vaccine news focuses on the global development race.
The latest poll comes amid protracted controversy over the cost of medicines, where there’s been little congressional or federal progress made despite bipartisan support for curing the high prices. Meanwhile, a new analysis warns about scientific research in the age of COVID.
The changes would allow commercial health insurers to enter into “value-based” payment schemes, the Centers for Medicare & Medicaid Services say.
President Donald Trump wants some people to be able to get the vaccine sooner than the end of the year to try to demonstrate that an end to the pandemic is within reach. Meanwhile, some worry that the vaccine race will leave poorer countries in the dust.
A cheap, common steroid significantly cuts the mortality rates in severe COVID-19 cases. While many public health leaders celebrated the news, some are more cautious. Meanwhile, WHO stops its trial of the controversial anti-malarial drug that has dangerous side effects and has yet to show any benefit for coronavirus patients.
ProPublica dives deep into the complications of creating a coronavirus vaccine with the quickest turnaround ever attempted. Meanwhile, drugmakers have a shortage of containers to put it in.
The “significant” results from the Oxford University research shows that dexamethasone reduces mortality in severely ill patients. Some scientists remain cautious though, wanting to see the actual data. “We’ve been burned before,” Dr. Kathryn Hibbert, director of the medical intensive care unit at Harvard’s Massachusetts General Hospital, tells Reuters.
Read about the biggest pharmaceutical development and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.
Trials using healthy volunteers would speed up the development of a safe vaccine for everyone else. But scientists and ethicists are still debating where that falls on the ethical spectrum of risk and benefits. In other news: how super antibodies could lead to a vaccine; Moderna projects a fall release of efficacy data; and more.
The FDA’s decision to revoke the authorization of hydroxychloroquine sends the message that “hospitals, doctors, patients and families really think twice,” said Jessie Goodman, a former FDA chief scientist. The drug, which President Donald Trump has touted and said he took, can have dangerous side effects and has yet to show any benefits in studies for COVID-19 patients.
Some experts worry that the intense political pressure for a vaccine by the end of the year might lead the Trump administration to rewrite safety rules. In other vaccine news: trials, supply agreements, costs and more.